Immunocore Holdings plc Depreciation
Immunocore Holdings plc (IMCR) reported Depreciation of $1.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Immunocore Holdings plc depreciation for the quarter ending 2026-06-30 was $1.03M, a 31.54% increase year-over-year.
- Immunocore Holdings plc depreciation for the quarter ending 2026-03-31 was $948.00K, a 11.01% increase year-over-year.
- Immunocore Holdings plc depreciation for the quarter ending 2025-12-31 was $834.00K, a 28.47% decline year-over-year.
- Immunocore Holdings plc depreciation for the quarter ending 2025-09-30 was $798.00K, a 22.90% decline year-over-year.
- Immunocore Holdings plc depreciation for fiscal 2025 was $3.27M, a 22.31% decline from fiscal 2024.
- Immunocore Holdings plc depreciation for fiscal 2024 was $4.20M, a 2.79% increase from fiscal 2023.
- Immunocore Holdings plc depreciation for fiscal 2023 was $4.09M, a 23.34% decline from fiscal 2022.
- Immunocore Holdings plc depreciation for fiscal 2022 was $5.33M, a 29.72% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.97M 10-Q · filed 2026-08-06 | $2.81M derived: sum of 3 quarters · filed 2026-08-06 | $3.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $948.00K 10-Q · filed 2026-05-06 | $1.78M derived: sum of 2 quarters · filed 2026-05-06 | $2.58M derived: sum of 3 quarters · filed 2026-05-06 | $3.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $834.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.63M derived: sum of 2 quarters · filed 2026-02-25 | $2.41M derived: sum of 3 quarters · filed 2026-08-06 | $3.27M 10-K · filed 2026-02-25 |
| 2025-09-30 | $798.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.58M derived: sum of 2 quarters · filed 2026-08-06 | $2.43M 10-Q · filed 2025-11-06 | $3.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.63M 10-Q · filed 2026-08-06 | $2.80M derived: sum of 3 quarters · filed 2026-08-06 | $3.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $854.00K 10-Q · filed 2026-05-06 | $2.02M derived: sum of 2 quarters · filed 2026-05-06 | $3.06M derived: sum of 3 quarters · filed 2026-05-06 | $4.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.20M derived: sum of 2 quarters · filed 2026-02-25 | $3.19M derived: sum of 3 quarters · filed 2026-02-25 | $4.20M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.03M derived: sum of 2 quarters · filed 2025-11-06 | $3.04M 10-Q · filed 2025-11-06 | $4.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $992.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.00M 10-Q · filed 2025-08-07 | $3.04M derived: sum of 3 quarters · filed 2026-02-25 | $4.11M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $1.01M 10-Q · filed 2025-05-07 | $2.04M derived: sum of 2 quarters · filed 2026-02-25 | $3.12M derived: sum of 3 quarters · filed 2026-02-25 | $4.15M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.11M derived: sum of 2 quarters · filed 2026-02-25 | $3.14M derived: sum of 3 quarters · filed 2026-02-25 | $4.09M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.11M derived: sum of 2 quarters · filed 2024-11-06 | $3.06M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.98M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $952.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $5.33M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $7.59M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |